Status:
COMPLETED
Minocyclin in Ulcerative Colitis as Added on Therapy
Lead Sponsor:
Mostafa Bahaa
Collaborating Sponsors:
Amira Fawzy Mohamed Mashaly, Clinical Pharmacy Demonstrator, Faculty of Pharmacy- Horus University
Tanta University
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immun...
Detailed Description
Most conventional UC therapies rely primarily on downregulating aberrant immune responses and inflammatory cascades. Mesalamine and corticosteroids are the mainstays in management of UC. However, 20% ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Exclusion
- Patients with severe UC Pregnancy and lactating females Significant liver and kidney function abnormalities Diabetic patients Patients with Colorectal cancer patients Patients taking rectal or systemic steroids Patients on immunosuppressants or biological therapies Patients taking antacids, anticoagulants, bactericidal antibiotics, oral contraceptives, and isotretinoin.
- Addiction to alcohol and / or drugs Known allergy to the studied medications History of complete or partial colectomy.
Key Trial Info
Start Date :
January 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06201793
Start Date
January 22 2024
End Date
January 20 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Mansoura University
Al Mansurah, Egypt, 7650001